SEC Tracker
Get the app

Protalix BioTherapeutics PLX

Protalix BioTherapeutics reports Q3 2026 financial results

Protalix BioTherapeutics (PLX) filed an 8-K with the SEC on Nov 10, 2026, 6:54 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Total revenues increased to $75.6 million year to date from $43.6 million in 2025
  2. Net income was $4.0 million for Q3 2026, up from $2.4 million in Q3 2025
  3. Cash and cash equivalents were $48.5 million as of September 30, 2026
  4. PRX-115 Phase 2 RELEASE study expects top-line results in 2027

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Protalix BioTherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.